Efficacy of a Novel Biphasic Controlled-Release Methylphenidate Formula in Adults With Attention-Deficit/Hyperactivity Disorder

Treatment of adults with attention-deficit/hyperactivity disorder

“…Results of a randomized, multicenter, double-blind, placebo-controlled, crossover study in 39 adults with ADHD demonstrated signifi cant behavioral improvement in those who received controlled released MPH compared with those who received the placebo. The treatment was well tolerated, and there were no serious adverse events (Jain et al 2007).…”

Steady-State Bioavailability of Extended-Release Methylphenidate (MPH-MLR) Capsule vs. Immediate-Release Methylphenidate Tablets in Healthy Adult Volunteers

“…The remaining 63 % of methylphenidate, following a morning administration of MPH-MLR, was designed to sustain a plateau in plasma drug concentration *5 h post dose, followed by a second more moderate ascent in plasma drug concentration in the afternoon. Oncedaily MPH-MLR was reported to be associated with improvements in behavior and cognition as evaluated using a variety of measures (e.g., Clinical Global Impressions scale, Inattention/Overactivity With Aggression Conners scale, Child's Behavior in Problem Situations scale, Communicative Pragmatics scale, and Conners' Adult ADHD rating scale) when given to children [23,25,26] and adults [27] with ADHD across home, simulated school, and work settings.…”

Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride

“…53 Long-acting preparations have a similar efficacy rate with greater convenience and compliance due to single daily dosing. 32,[55][56][57][58][59] In one study, once daily dosing of equipotent extended-release OROS MPH tablets (Concerta ® ) had similar efficacy to 3 times per day dosing of immediaterelease MPH. 59 In a double-blind trial of 401 adults with ADHD, those treated with OROS methylphenidate (18 mg, 36 mg, or 72 mg/day), demonstrated significant improvement in total symptom score as measured by Connor's Adult ADHD Rating Scale (mean change = -10.6 for 18 mg, P = 0.01; -11.5 for 36 mg, P = 0.01; -13.7 for 72 mg, P  0.001; -7.6 for placebo).…”

“…32,55,56 Patients appear to be fairly tolerant of side effects, one study showing only 4.3% of patients treated with OROS MPH discontinuing treatment due to an adverse event. 55 MPH preparations should be used with caution in patients with prior history of seizure disorders as it can initiate seizures in higher doses.…”